ecancermedicalscience

Review

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives

7 Jan 2016
Romualdo Barroso-Sousa, Danilo Fonseca Reis Silva, Joao Victor Machado Alessi, Max Senna Mano

Luminal breast cancer, as defined by oestrogen and/or progesterone expression by immunohistochemistry, accounts for up to 75% of all breast cancers. In this population, endocrine therapy is likely to account for most of the gains obtained with the administration of adjuvant systemic treatment. The role of adjuvant chemotherapy in these patients remains debatable since it is known that only a small fraction of patients will derive meaningful benefit from this treatment whilst the majority will be exposed to significant and unnecessary chemotherapy-related toxicities, in particular the elderly and frail. Therefore, neoadjuvant endocrine therapy (NET) becomes an attractive option for selected patients with hormonal-receptor positive locally advanced breast cancer. In this review, we discuss the current role of NET and future perspectives in the field.

Article metrics: 14773 views
1071
13702

Related Articles

Francisco Trinca, Paulo Infante, Rui Dinis, Mariana Inácio, Emílio Bravo, Jorge Caravana, Teresa Reis, Sofia Marques
Diana Carolina Sotelo-Rodríguez, Alejandro Ruíz-Patiño, Luisa Ricaurte, Oscar Arrieta, Zyanya Lucia Zatarain-Barrón, Andrés F Cardona
Cesar Sánchez, Mauricio Camus, Cristóbal Maiz, David Oddó, María Elena Navarro, Catalina Vargas, Marisa Bustos
Alberto Rancati, Raghavan Vidya, Giorgio Berna, Hani Sbitany, Maurice Nahabedian, Hilton Becker, Roland Reitsamer, Douglas Macmillan, Simon Cawthorn